After this activity, the learner should be able to:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC, the Dermatology Education Foundation, and Physician Resources, LLC. Evolve Medical Education, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Evolve Medical Education, LLC designates this enduring material for a maximum of .5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA CONTINUING EDUCATION
PAs may claim a maximum of .5 Category 1 credits for completing this activity. National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
NURSE PRACTITIONER CONTINUING EDUCATION
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Leon Kircik, MD, FAAD; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant: Aclaris Therapeutics, Almirall, S.A., Amgen Inc., Celgene, Dr. Reddy’s Laboratories, Innovail, ISDIN, Kamedis Dermatology, Leo Pharma, Inc., Merck & Co, Inc., Merz, Inc., Novartis, AG, Promius Pharma, LLC, PuraCap Pharmaceutical, Taro Pharmaceuticals Inc. and UCB, SA. Consultant/Advisory Board/Speakers Bureau: Allergan, Inc., Inc., Cipher Pharmaceuticals, Galderma Laboratories, LP, Genentech, Inc., Johnson & Johnson, Sun Pharmaceutical Industries, Inc., and Valeant Pharmaceuticals, Intl. Speakers Bureau: Amgen Inc., Innovail, L’Oreal, Taro Pharmaceuticals Inc. and UCB, SA. Grant/Research Support: Allergan, Inc., Amgen, Inc., Bayer HealthCare Pharmaceuticals, Boehringer Ingleheim, Celgene, Coherus Biosciences, Dermavant Sciences, Dermira, Inc., Dr. Reddy’s Laboratories, Eli Lilly, Galderma Laboratories, Genentech, Inc, Innovation Pharmaceuticals, Inc, Johnson & Johnson, Kamedis Dermatology, Leo Pharma, Inc., L’Oreal, Merck & Co, Inc., Novartis, AG,, Novan Pharmaceuticals, Obagi Cosmeceuticals, LLC., Promius Pharma, LLC., Pfzer, Inc., Sun Pharmaceutical Industries, Inc., UCB, SA, and Valeant Pharmaceuticals, Intl. ( Ortho Dermatologics). Stock Shareholder: Johnson & Johnson.